688131 皓元医药
已收盘 10-23 15:00:00
资讯
新帖
简况
皓元医药（688131）披露“皓元转债”预计满足赎回条件的提示性公告，10月23日股价上涨2.4%
证券之星 · 10-23 22:38
皓元医药（688131）披露“皓元转债”预计满足赎回条件的提示性公告，10月23日股价上涨2.4%
皓元医药（688131）10月19日主力资金净买入846.30万元
证券之星 · 10-20
皓元医药（688131）10月19日主力资金净买入846.30万元
皓元医药（688131）10月16日主力资金净卖出643.72万元
证券之星 · 10-17
皓元医药（688131）10月16日主力资金净卖出643.72万元
10月16日皓元医药跌5.48%，科创创新药ETF国泰基金重仓该股
证券之星 · 10-16
10月16日皓元医药跌5.48%，科创创新药ETF国泰基金重仓该股
皓元医药（688131）10月13日主力资金净买入2062.43万元
证券之星 · 10-14
皓元医药（688131）10月13日主力资金净买入2062.43万元
股市必读：皓元医药新发布《上海皓元医药股份有限公司可转债转股结果暨股份变动公告》
证券之星 · 10-12
股市必读：皓元医药新发布《上海皓元医药股份有限公司可转债转股结果暨股份变动公告》
皓元医药（688131）披露可转债转股结果暨股份变动公告，10月8日股价下跌5.35%
证券之星 · 10-08
皓元医药（688131）披露可转债转股结果暨股份变动公告，10月8日股价下跌5.35%
皓元医药（688131）9月24日主力资金净卖出3053.70万元
证券之星 · 09-25
皓元医药（688131）9月24日主力资金净卖出3053.70万元
9月24日皓元医药跌6.19%，科创创新药ETF国泰基金重仓该股
证券之星 · 09-24
9月24日皓元医药跌6.19%，科创创新药ETF国泰基金重仓该股
皓元医药（688131）9月23日主力资金净卖出1.04亿元
证券之星 · 09-24
皓元医药（688131）9月23日主力资金净卖出1.04亿元
9月23日皓元医药涨9.84%，科创创新药ETF国泰基金重仓该股
证券之星 · 09-23
9月23日皓元医药涨9.84%，科创创新药ETF国泰基金重仓该股
皓元医药涨9.84%，开源证券三周前给出“买入”评级
证券之星 · 09-23
皓元医药涨9.84%，开源证券三周前给出“买入”评级
每周股票复盘：皓元医药（688131）每股派现0.09元含税
证券之星 · 09-20
每周股票复盘：皓元医药（688131）每股派现0.09元含税
【机构调研记录】嘉实基金调研皓元医药、中科飞测
证券之星 · 09-14
【机构调研记录】嘉实基金调研皓元医药、中科飞测
【机构调研记录】华宝基金调研联化科技、皓元医药等3只个股（附名单）
证券之星 · 09-14
【机构调研记录】华宝基金调研联化科技、皓元医药等3只个股（附名单）
【机构调研记录】中银基金调研云南锗业、皓元医药
证券之星 · 09-14
【机构调研记录】中银基金调研云南锗业、皓元医药
【私募调研记录】磐耀资产调研皓元医药
证券之星 · 09-14
【私募调研记录】磐耀资产调研皓元医药
股市必读：皓元医药新发布《上海皓元医药股份有限公司股东减持股份计划公告》
证券之星 · 09-14
股市必读：皓元医药新发布《上海皓元医药股份有限公司股东减持股份计划公告》
每周股票复盘：皓元医药（688131）Q2境外收入达6.9亿元
证券之星 · 09-13
每周股票复盘：皓元医药（688131）Q2境外收入达6.9亿元
皓元医药：9月3日接受机构调研，包括知名机构磐耀资产的多家机构参与
证券之星 · 09-12
皓元医药：9月3日接受机构调研，包括知名机构磐耀资产的多家机构参与
加载更多
公司概况
公司名称：
上海皓元医药股份有限公司
所属行业：
研究和试验发展
上市日期：
2021-06-08
主营业务：
上海皓元医药股份有限公司的主营业务是药物发现领域的生命科学试剂的研发，原料药、中间体、起始物料及制剂的药物研发，工艺优化及商业化生产。公司的主要产品是生命科学试剂业务、原料药和中间体、制剂业务。
发行价格：
64.99
{"stockData":{"symbol":"688131","market":"SH","secType":"STK","nameCN":"皓元医药","latestPrice":83.99,"timestamp":1792738800000,"preClose":82.02,"halted":0,"volume":4166354,"delay":0,"changeRate":0.024,"floatShares":213000000,"shares":213000000,"eps":1.2158,"marketStatus":"已收盘","change":1.97,"latestTime":"10-23 15:00:00","open":81.1,"high":84.63,"low":78.86,"amount":339000000,"amplitude":0.0703,"askPrice":84,"askSize":13,"bidPrice":83.99,"bidSize":129,"shortable":0,"etf":0,"ttmEps":1.2158,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1792978200000},"marketStatusCode":5,"adr":0,"adjPreClose":82.02,"symbolType":"stock_kcb","openAndCloseTimeList":[[1792719000000,1792726200000],[1792731600000,1792738800000]],"highLimit":90.22,"lowLimit":73.82,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":213234116,"isCdr":false,"pbRate":5.56,"roa":"--","peRate":69.082086,"roe":"5.3%","epsLYR":1.13,"committee":0.555556,"marketValue":17910000000,"turnoverRate":0.0195,"status":0,"afterMarket":{"amount":0,"volume":0,"close":83.99,"buyVolume":3500,"sellVolume":0,"time":1792740837746,"indexStatus":"已收盘 10-23 15:30:00","preClose":82.02},"floatMarketCap":17910000000},"requestUrl":"/m/hq/s/688131","defaultTab":"news","newsList":[{"id":"2677973641","title":"皓元医药（688131）披露“皓元转债”预计满足赎回条件的提示性公告，10月23日股价上涨2.4%","url":"https://stock-news.laohu8.com/highlight/detail?id=2677973641","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2677973641?lang=zh_cn&edition=full","pubTime":"2026-10-23 22:38","pubTimestamp":1792766310,"startTime":"0","endTime":"0","summary":"截至2026年10月23日收盘，皓元医药报收于83.99元，较前一交易日上涨2.4%，最新总市值为179.1亿元。该股当日开盘81.1元，最高84.63元，最低78.86元，成交额达3.39亿元，换手率为1.95%。近日，上海皓元医药股份有限公司发布《关于“皓元转债”预计满足赎回条件的提示性公告》。公告显示，“皓元转债”自2026年10月12日至10月23日已有10个交易日收盘价不低于当期转股价格的130%。公司将按规定履行信息披露义务，提醒投资者关注赎回风险。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102300045829.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688131","BK0216"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2676320686","title":"皓元医药（688131）10月19日主力资金净买入846.30万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2676320686","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2676320686?lang=zh_cn&edition=full","pubTime":"2026-10-20 08:22","pubTimestamp":1792455739,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2026年10月19日收盘，皓元医药报收于83.55元，上涨2.6%，换手率2.68%，成交量5.72万手，成交额4.68亿元。10月19日的资金流向数据方面，主力资金净流入846.3万元，占总成交额1.81%，游资资金净流入2327.94万元，占总成交额4.97%，散户资金净流出3174.24万元，占总成交额6.78%。近5日资金流向一览见下表：皓元医药融资融券信息显示，融资方面，当日融资买入3668.53万元，融资偿还3442.37万元，融资净买入226.16万元，连续3日净买入累计3032.86万元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102000005129.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688131","BK0216"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2676510691","title":"皓元医药（688131）10月16日主力资金净卖出643.72万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2676510691","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2676510691?lang=zh_cn&edition=full","pubTime":"2026-10-17 08:21","pubTimestamp":1792196487,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2026年10月16日收盘，皓元医药报收于81.43元，下跌5.48%，换手率2.81%，成交量5.99万手，成交额5.07亿元。10月16日的资金流向数据方面，主力资金净流出643.72万元，占总成交额1.27%，游资资金净流入4063.57万元，占总成交额8.02%，散户资金净流出3419.86万元，占总成交额6.75%。融券方面，融券卖出1200.0股，融券偿还1140.0股，融券余量6.55万股，融券余额533.55万元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026101700005761.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","688131"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675562252","title":"10月16日皓元医药跌5.48%，科创创新药ETF国泰基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2675562252","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2675562252?lang=zh_cn&edition=full","pubTime":"2026-10-16 16:31","pubTimestamp":1792139480,"startTime":"0","endTime":"0","summary":"证券之星消息，10月16日皓元医药跌5.48%，收盘报81.43元，换手率2.81%，成交量5.99万手，成交额5.07亿元。根据2026基金半年报公募基金重仓股数据，重仓该股的公募基金共28家，其中持有数量最多的公募基金为国泰基金的科创创新药ETF国泰。科创创新药ETF国泰目前规模为21.97亿元，最新净值0.7888，较上一交易日下跌0.6%，近一年下跌16.32%。科创创新药ETF国泰的前十大重仓股如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026101600027874.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["589720","688131","BK0216"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675395760","title":"皓元医药（688131）10月13日主力资金净买入2062.43万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2675395760","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2675395760?lang=zh_cn&edition=full","pubTime":"2026-10-14 08:27","pubTimestamp":1791937645,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2026年10月13日收盘，皓元医药报收于88.36元，下跌2.9%，换手率2.78%，成交量5.94万手，成交额5.16亿元。10月13日的资金流向数据方面，主力资金净流入2062.43万元，占总成交额4.0%，游资资金净流入1229.48万元，占总成交额2.38%，散户资金净流出3291.91万元，占总成交额6.38%。近5日资金流向一览见下表：皓元医药融资融券信息显示，融资方面，当日融资买入4957.13万元，融资偿还4130.93万元，融资净买入826.2万元，连续3日净买入累计3245.6万元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026101400007210.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","688131"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674532846","title":"股市必读：皓元医药新发布《上海皓元医药股份有限公司可转债转股结果暨股份变动公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2674532846","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2674532846?lang=zh_cn&edition=full","pubTime":"2026-10-12 03:28","pubTimestamp":1791746893,"startTime":"0","endTime":"0","summary":"当日关注点交易信息汇总：10月9日主力资金净流出375.43万元，游资资金净流入3007.03万元。公司公告汇总上海皓元医药股份有限公司可转债转股结果暨股份变动公告截至2026年9月30日，累计已有514,000元“皓元转债”转换为公司股票，累计转股数量为12,640股，占转股前公司总股本的0.0060%；本季度新增转股1,000元，对应转股数量24股；未转股可转债金额为821,836,000元，占发行总量的99.94%；公司总股本因转股增加至213,234,116股；最新转股价格为40.13元/股。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026101200001108.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","688131"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673500305","title":"皓元医药（688131）披露可转债转股结果暨股份变动公告，10月8日股价下跌5.35%","url":"https://stock-news.laohu8.com/highlight/detail?id=2673500305","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2673500305?lang=zh_cn&edition=full","pubTime":"2026-10-08 22:29","pubTimestamp":1791469749,"startTime":"0","endTime":"0","summary":"截至2026年10月8日收盘，皓元医药报收于94.15元，较前一交易日下跌5.35%，最新总市值为200.76亿元。近日，公司发布《上海皓元医药股份有限公司可转债转股结果暨股份变动公告》。公告显示，截至2026年9月30日，累计已有514,000元“皓元转债”转换为公司股票，累计转股数量为12,640股，占转股前公司总股本的0.0060%。本季度转股期间为2026年7月1日至9月30日，共1,000元转债转股，转股数量24股。公司总股本因转股增加至213,234,116股。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026100800034643.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688131","BK0216"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670419937","title":"皓元医药（688131）9月24日主力资金净卖出3053.70万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2670419937","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2670419937?lang=zh_cn&edition=full","pubTime":"2026-09-25 08:23","pubTimestamp":1790295828,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2026年9月24日收盘，皓元医药报收于103.54元，下跌6.19%，换手率3.18%，成交量6.77万手，成交额7.24亿元。9月24日的资金流向数据方面，主力资金净流出3053.7万元，占总成交额4.22%，游资资金净流出3929.95万元，占总成交额5.42%，散户资金净流入6983.66万元，占总成交额9.64%。融券方面，融券卖出0.0股，融券偿还3218.0股，融券余量6.71万股，融券余额695.0万元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092500005102.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688131","BK0216"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669631874","title":"9月24日皓元医药跌6.19%，科创创新药ETF国泰基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2669631874","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669631874?lang=zh_cn&edition=full","pubTime":"2026-09-24 16:37","pubTimestamp":1790239071,"startTime":"0","endTime":"0","summary":"证券之星消息，9月24日皓元医药跌6.19%创60日新高，收盘报103.54元，换手率3.18%，成交量6.77万手，成交额7.24亿元。根据2026基金半年报公募基金重仓股数据，重仓该股的公募基金共28家，其中持有数量最多的公募基金为国泰基金的科创创新药ETF国泰。科创创新药ETF国泰目前规模为21.97亿元，最新净值0.9454，较上一交易日上涨2.12%，近一年下跌6.99%。科创创新药ETF国泰的前十大重仓股如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092400028534.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","589720","688131"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669432457","title":"皓元医药（688131）9月23日主力资金净卖出1.04亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2669432457","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669432457?lang=zh_cn&edition=full","pubTime":"2026-09-24 08:13","pubTimestamp":1790208796,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2026年9月23日收盘，皓元医药报收于110.37元，上涨9.84%，换手率4.96%，成交量10.58万手，成交额11.45亿元。9月23日的资金流向数据方面，主力资金净流出1.04亿元，占总成交额9.08%，游资资金净流入2142.52万元，占总成交额1.87%，散户资金净流入8249.88万元，占总成交额7.21%。近5日资金流向一览见下表：皓元医药融资融券信息显示，融资方面，当日融资买入1.02亿元，融资偿还1.12亿元，融资净偿还992.47万元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092400007622.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","688131"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669109679","title":"9月23日皓元医药涨9.84%，科创创新药ETF国泰基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2669109679","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669109679?lang=zh_cn&edition=full","pubTime":"2026-09-23 16:37","pubTimestamp":1790152655,"startTime":"0","endTime":"0","summary":"证券之星消息，9月23日皓元医药涨9.84%创60日新高，收盘报110.37元，换手率4.96%，成交量10.58万手，成交额11.45亿元。根据2026基金半年报公募基金重仓股数据，重仓该股的公募基金共28家，其中持有数量最多的公募基金为国泰基金的科创创新药ETF国泰。科创创新药ETF国泰目前规模为21.97亿元，最新净值0.9258，较上一交易日上涨0.33%，近一年下跌11.79%。科创创新药ETF国泰的前十大重仓股如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092300028183.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","589720","688131"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669109945","title":"皓元医药涨9.84%，开源证券三周前给出“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2669109945","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669109945?lang=zh_cn&edition=full","pubTime":"2026-09-23 16:37","pubTimestamp":1790152644,"startTime":"0","endTime":"0","summary":"今日皓元医药涨9.84%，收盘报110.37元。2026年8月28日，开源证券研究员余汝意发布了对皓元医药的研报《公司信息更新报告：前端业务高景气驱动收入增长，后端订单加速蓄能》，该研报对皓元医药给出“买入”评级。研报中预计2026-2028年公司归母净利润为3.51/5.26/7.20亿元，EPS为1.65/2.47/3.38元，当前股价对应PE为56.9/37.9/27.7倍，维持“买入”评级。皓元医药个股概况：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092300028179.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["161027","688131"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668906777","title":"每周股票复盘：皓元医药（688131）每股派现0.09元含税","url":"https://stock-news.laohu8.com/highlight/detail?id=2668906777","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2668906777?lang=zh_cn&edition=full","pubTime":"2026-09-20 01:36","pubTimestamp":1789839372,"startTime":"0","endTime":"0","summary":"截至2026年9月18日收盘，皓元医药报收于98.79元，较上周的87.28元上涨13.19%。本周，皓元医药9月18日盘中最高价报100.76元。本周关注点公司公告汇总：皓元医药每股派发现金红利0.09元（含税）。公司总股本为213,234,116股，合计派发现金红利19,191,070.44元（含税）。上海皓元医药股份有限公司关于调整2026年半年度利润分配现金分红总额的公告：2026年半年度拟向全体股东每10股派发现金红利0.90元（含税），每股分配金额保持不变。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092000000320.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","688131"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667003635","title":"【机构调研记录】嘉实基金调研皓元医药、中科飞测","url":"https://stock-news.laohu8.com/highlight/detail?id=2667003635","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2667003635?lang=zh_cn&edition=full","pubTime":"2026-09-14 08:02","pubTimestamp":1789344124,"startTime":"0","endTime":"0","summary":"证券之星消息，根据市场公开信息及9月11日披露的机构调研信息，嘉实基金近期对2家上市公司进行了调研，相关名单如下：1）皓元医药 调研纪要：2026年上半年，分子砌块业务收入3.53亿元，同比增长37.1%，储备约11.3万种；工具化合物和生化试剂收入8.6亿元，同比增长32.8%，累计储备约18.2万种。2）中科飞测 调研纪要：2026年上半年，公司收入及订单结构整体正在发生积极变化。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026091400002276.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["SGXZ49509284.SGD","BK0216","688131","SGXZ81163826.USD","688361","BK0251"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667636833","title":"【机构调研记录】华宝基金调研联化科技、皓元医药等3只个股（附名单）","url":"https://stock-news.laohu8.com/highlight/detail?id=2667636833","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2667636833?lang=zh_cn&edition=full","pubTime":"2026-09-14 08:01","pubTimestamp":1789344119,"startTime":"0","endTime":"0","summary":"证券之星消息，根据市场公开信息及9月11日披露的机构调研信息，华宝基金近期对3家上市公司进行了调研，相关名单如下：1）联化科技 调研纪要：公司2026年上半年利润同比高增，主要得益于医药业务集中发货及新能源板块收入放量，后者收入同比增长193.63%。涨价订单将在2026年四季度签署，2027年业绩将逐步体现。预计2027年毛利率持续增长，净利润将转正。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026091400002272.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0118","002250","BK0216","BK0028","BK0188","688131","BK0070","BK0229"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667026635","title":"【机构调研记录】中银基金调研云南锗业、皓元医药","url":"https://stock-news.laohu8.com/highlight/detail?id=2667026635","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2667026635?lang=zh_cn&edition=full","pubTime":"2026-09-14 08:01","pubTimestamp":1789344111,"startTime":"0","endTime":"0","summary":"证券之星消息，根据市场公开信息及9月11日披露的机构调研信息，中银基金近期对2家上市公司进行了调研，相关名单如下：1）云南锗业 调研纪要：2026年上半年，国内锗市场价格重心上移，原料供应偏紧。2）皓元医药 调研纪要：2026年上半年，分子砌块业务收入3.53亿元，同比增长37.1%，储备约11.3万种；工具化合物和生化试剂收入8.6亿元，同比增长32.8%，累计储备约18.2万种。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026091400002259.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0233","BK0182","002428","BK0028","688131","BK0216"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667848636","title":"【私募调研记录】磐耀资产调研皓元医药","url":"https://stock-news.laohu8.com/highlight/detail?id=2667848636","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2667848636?lang=zh_cn&edition=full","pubTime":"2026-09-14 08:00","pubTimestamp":1789344058,"startTime":"0","endTime":"0","summary":"根据市场公开信息及9月11日披露的机构调研信息，知名私募磐耀资产近期对1家上市公司进行了调研，相关名单如下：1）皓元医药 调研纪要：2026年上半年，分子砌块业务收入3.53亿元，同比增长37.1%，储备约11.3万种；工具化合物和生化试剂收入8.6亿元，同比增长32.8%，累计储备约18.2万种。在投资方法上，磐耀资产注重研究驱动的投资，强调严谨科学的投资流程在投资中的重要性。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://fund.stockstar.com/RB2026091400002220.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688131","BK0216"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667809176","title":"股市必读：皓元医药新发布《上海皓元医药股份有限公司股东减持股份计划公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2667809176","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2667809176?lang=zh_cn&edition=full","pubTime":"2026-09-14 01:56","pubTimestamp":1789322170,"startTime":"0","endTime":"0","summary":"公司公告汇总上海皓元医药股份有限公司股东减持股份计划公告截至公告披露日，上海臣骁持有公司3.92%股份，上海臣迈持有2.57%股份，上海臣曦持有1.29%股份；因员工个人资金需求，拟自公告披露之日起3个交易日后3个月内，通过集中竞价方式合计减持不超过4,990,000股，其中臣骁减持不超过1.00%，臣迈减持不超过0.34%，臣曦减持不超过1.00%；本次减持不会导致公司控制权变更。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026091400000769.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","688131"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667550714","title":"每周股票复盘：皓元医药（688131）Q2境外收入达6.9亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2667550714","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2667550714?lang=zh_cn&edition=full","pubTime":"2026-09-13 02:19","pubTimestamp":1789237150,"startTime":"0","endTime":"0","summary":"截至2026年9月11日收盘，皓元医药报收于87.28元，较上周的88.83元下跌1.74%。本周，皓元医药9月8日盘中最高价报96.4元。皓元医药当前最新总市值186.11亿元，在医疗服务板块市值排名8/51，在两市A股市值排名1027/5218。截至报告期末，累计储备约11.3万种分子砌块。2026年上半年，公司实现境外业务收入6.9亿元，同比增长约23.24%。权益分派股权登记日后的第一个交易日起恢复转股。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026091300000574.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","688131"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666157654","title":"皓元医药：9月3日接受机构调研，包括知名机构磐耀资产的多家机构参与","url":"https://stock-news.laohu8.com/highlight/detail?id=2666157654","media":"证券之星","labels":["conferences"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2666157654?lang=zh_cn&edition=full","pubTime":"2026-09-12 00:05","pubTimestamp":1789142724,"startTime":"0","endTime":"0","summary":"证券之星消息，2026年9月11日皓元医药发布公告称公司于2026年9月3日接受机构调研，中信建投证券、中银基金、兴证全球基金、国泰基金、万家基金、国金资管、瑞文投资、磐耀资产、申万宏源证券、平安证券、招商证券、华泰证券、东方财富证券、嘉实基金、华宝基金、长江养老参与。本次利润分配不送红股，不进行资本公积金转增股本。利润分配的具体实施安排请留意公司后续发布的权益分派实施公告。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026091200000238.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688131","BK0216"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1792950278329,"stockEarnings":[{"period":"1week","weight":0.0314},{"period":"1month","weight":-0.239},{"period":"3month","weight":0.2335},{"period":"6month","weight":0.1542},{"period":"1year","weight":0.0522},{"period":"ytd","weight":0.1683}],"compareEarnings":[{"period":"1week","weight":-0.0069},{"period":"1month","weight":-0.0625},{"period":"3month","weight":-0.0324},{"period":"6month","weight":-0.0954},{"period":"1year","weight":-0.0591},{"period":"ytd","weight":-0.0701}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"上海皓元医药股份有限公司","boardCode":"AI0073","boardName":"研究和试验发展","stockholders":"15882人(较上一季度增加33.43%)","perCapita":"13426股","listingDate":"2021-06-08","address":"上海市浦东新区中国(上海)自由贸易试验区蔡伦路720弄2号501室","registeredCapital":"21323万元","survey":" 上海皓元医药股份有限公司的主营业务是药物发现领域的生命科学试剂的研发，原料药、中间体、起始物料及制剂的药物研发，工艺优化及商业化生产。公司的主要产品是生命科学试剂业务、原料药和中间体、制剂业务。","listedPrice":64.99},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.52.0","shortVersion":"4.52.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"皓元医药(688131)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供皓元医药(688131)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"皓元医药,688131,皓元医药股票,皓元医药股票老虎,皓元医药股票老虎国际,皓元医药行情,皓元医药股票行情,皓元医药股价,皓元医药股市,皓元医药股票价格,皓元医药股票交易,皓元医药股票购买,皓元医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"皓元医药(688131)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供皓元医药(688131)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}